Your browser doesn't support javascript.
loading
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Sho Miyamoto; Takeshi Arashiro; Yu Adachi; Saya Moriyama; Hitomi Kinoshita; Takayuki Kanno; Shinji Saito; Harutaka Katano; Shun Iida; Akira Ainai; Ryutaro Kotaki; Souichi Yamada; Yudai Kuroda; Tsukasa Yamamoto; Keita Ishijima; Eun-Sil Park; Yusuke Inoue; Yoshihiro Kaku; Minoru Tobiume; Naoko Iwata-Yoshikawa; Nozomi Shiwa-Sudo; Kenzo Tokunaga; Seiya Ozono; Takuya Hemmi; Akira Ueno; Noriko Kishida; Shinji Watanabe; Kiyoko Nojima; Yohei Seki; Takuo Mizukami; Hideki Hasegawa; Hideki Ebihara; Ken Maeda; Shuetsu Fukushi; Yoshimasa Takahashi; Tadaki Suzuki.
Afiliação
  • Sho Miyamoto; National Institute of Infectious Diseases
  • Takeshi Arashiro; National Institute of Infectious Diseases
  • Yu Adachi; National Institute of Infectious Diseases
  • Saya Moriyama; National Institute of Infectious Diseases
  • Hitomi Kinoshita; National Institute of Infectious Diseases
  • Takayuki Kanno; National Institute of Infectious Diseases
  • Shinji Saito; National Institute of Infectious Diseases
  • Harutaka Katano; National Institute of Infectious Diseases
  • Shun Iida; National Institute of Infectious Diseases
  • Akira Ainai; National Institute of Infectious Diseases
  • Ryutaro Kotaki; National Institute of Infectious Diseases
  • Souichi Yamada; National Institute of Infectious Diseases
  • Yudai Kuroda; National Institute of Infectious Diseases
  • Tsukasa Yamamoto; National Institute of Infectious Diseases
  • Keita Ishijima; National Institute of Infectious Diseases
  • Eun-Sil Park; National Institute of Infectious Diseases
  • Yusuke Inoue; National Institute of Infectious Diseases
  • Yoshihiro Kaku; National Institute of Infectious Diseases
  • Minoru Tobiume; National Institute of Infectious Diseases
  • Naoko Iwata-Yoshikawa; National Institute of Infectious Diseases
  • Nozomi Shiwa-Sudo; National Institute of Infectious Diseases
  • Kenzo Tokunaga; National Institute of Infectious Diseases
  • Seiya Ozono; National Institute of Infectious Diseases
  • Takuya Hemmi; National Institute of Infectious Diseases
  • Akira Ueno; National Institute of Infectious Diseases
  • Noriko Kishida; National Institute of Infectious Diseases
  • Shinji Watanabe; National Institute of Infectious Diseases
  • Kiyoko Nojima; National Institute of Infectious Diseases
  • Yohei Seki; National Institute of Infectious Diseases
  • Takuo Mizukami; National Institute of Infectious Diseases
  • Hideki Hasegawa; National Institute of Infectious Diseases
  • Hideki Ebihara; National Institute of Infectious Diseases
  • Ken Maeda; National Institute of Infectious Diseases
  • Shuetsu Fukushi; National Institute of Infectious Diseases
  • Yoshimasa Takahashi; National Institute of Infectious Diseases
  • Tadaki Suzuki; National Institute of Infectious Diseases
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21268481
ABSTRACT
BackgroundThe immune profile against SARS-CoV-2 has dramatically diversified due to a complex combination of exposure to vaccines and infection by various lineages/variants, likely generating a heterogeneity in protective immunity in a given population. To further complicate this, the Omicron variant, with numerous spike mutations, has emerged. These circumstances have created the need to assess the potential of immune evasion by the Omicron in individuals with various immune histories. MethodsThe neutralization susceptibility of the variants including the Omicron and their ancestor was comparably assessed using a panel of plasma/serum derived from individuals with divergent immune histories. Blood samples were collected from either mRNA vaccinees or from those who suffered from breakthrough infections by the Alpha/Delta with multiple time intervals following vaccination. FindingsThe Omicron was highly resistant to neutralization in fully vaccinated individuals without a history of breakthrough infections. In contrast, robust cross-neutralization against the Omicron were induced in vaccinees that experienced breakthrough infections. The time interval between vaccination and infection, rather than the variant types of infection, was significantly correlated with the magnitude and potency of Omicron-neutralizing antibodies. ConclusionsImmune histories with breakthrough infections can overcome the resistance to infection by the Omicron, with the vaccination-infection interval being the key determinant of the magnitude and breadth of neutralization. The diverse exposure history in each individual warrants a tailored and cautious approach to understanding population immunity against the Omicron and future variants. FundingThis study was supported by grants from the Japan Agency for Medical Research and Development (AMED).
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Prognostic_studies / Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Prognostic_studies / Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
...